Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial
Stefano Cascinu, Rossana Berardi, Roberto Bianco, Domenico Bilancia, Alberto Zaniboni, Daris Ferrari, Stefania Mosconi, Andrea Spallanzani, Luigi Cavanna, Silvana Leo, Francesca Negri, Giordano Beretta, Alberto Sobrero, Maria Banzi, Alberto Morabito, Alessandro Bittoni, Roberta Marciano, Domenica Ferrara, Silvia Noventa, Maria Carmela Piccirillo, Roberto Labianca, Cristina Mosconi, Andrea Casadei‐Gardini, Ciro Gallo, Francesco Perrone
Topics & Concepts
GemcitabineMedicineInternal medicinePancreatic cancerClinical endpointChemotherapyGastroenterologyPhases of clinical researchProgressive diseasePaclitaxelRandomized controlled trialDeoxycytidineProgression-free survivalCancerOncologySurgeryUrologyPancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer StudiesNeuroendocrine Tumor Research Advances